
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934**
For the Month of May 2026
(Commission File No. 001-41636)

Oculus Holding AG
(Translation of registrant's name into English)

**Bahnhofstrasse 20
CH-6300
Zug, Switzerland**
(Address of registrant's principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F Form 40-F

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On May 29, 2026, Oculis Holding AG (the “Registrant”) announced topline data from its DIAMOND Phase 3 trials of OCS-01 for the treatment of diabetic macular edema and held a conference call to discuss the results. The press release and the corporate presentation presented during the conference call are furnished hereto as Exhibits 99.1 and 99.2, respectively.

Exhibits 99.1 and 99.2 are hereby incorporated by reference into the Registrant’s Registration Statements on Form S-8 (File No. 333-271938 and 333-287806) and Form F-3 (File Nos. 333-294011, 333-278409, 333-271063 and 333-291426).

EXHIBIT INDEX

Exhibit	Description
99.1	Press Release dated May 29, 2026
99.2	Corporate Presentation dated May 29, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

OCULIS HOLDING AG

Date: May 29, 2026

By: /s/ Sylvia Cheung
Sylvia Cheung
Chief Financial Officer



Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

- *The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met*
 - *The secondary endpoint of retinal thickness showed a substantial and persistent reduction with OCS-01 vs vehicle in both trials*
- *Oculis will focus its developmental efforts and financial resources on the ongoing Privosector PIONEER registrational program in optic neuropathies and the Licaminlimab PREDICT-1 registrational trial in dry eye disease*
- *Financial position remains strong with \$278 million in cash, cash equivalents, and short-term investments as of March 31, 2026, providing cash runway into 2H 2029*

Conference call today at 4:30 pm ET

ZUG, Switzerland, 29 May, 2026 – Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced topline results from its Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in patients with diabetic macular edema (DME).

The DIAMOND (DIAbetic Macular edema patients ON a Drop) program consisted of two Phase 3, double-masked, randomized, multi-center trials to evaluate the efficacy and safety of OCS-01 eye drops in patients with DME following 52 weeks of treatment. Over 800 patients were enrolled across both pivotal trials at 119 investigational sites throughout the United States and several other countries.

The primary endpoint, mean change in best corrected visual acuity early treatment diabetic retinopathy study (BCVA ETDRS) letter score at Week 52, was not met in both trials. The secondary endpoint of retinal thickness, as measured by OCT, showed a substantial and persistent reduction with OCS-01 vs vehicle at all visits in DIAMOND-2 and at all visits except Week 52 in DIAMOND-1. The key secondary endpoint of the proportion of patients with ≥ 15 -letter gain in BCVA was not met in both trials.

OCS-01 was well tolerated, with no unexpected adverse events observed, and the overall safety profile was consistent with that of previous trials.

Based on the results, at this time, Oculis does not plan to pursue an FDA regulatory filing for OCS-01 in DME.

Riad Sherif, M.D., Chief Executive Officer of Oculis, said: "We are naturally disappointed that the substantial and sustained reduction in retinal thickness observed across both trials didn't translate into BCVA improvement at week 52. In these two trials, our team partnered with 119 global sites across multiple countries and demonstrated excellent execution. We thank the patients, investigators, and all



clinical experts who participated in the DIAMOND program. Our strong financial position allows us to execute on our robust late-stage development portfolio. While we finalize the review of DIAMOND program data, we will strategically focus resources on advancing our late-stage portfolio, including the Privosegtor platform, starting with the PIONEER program for Privosegtor in optic neuropathies, and the PREDICT-1 trial for Licaminlimab to drive precision medicine in dry eye disease."

Analyst and investor call

The Oculis management team will host an analyst and investor call today at 4:30 pm U.S. Eastern Time, to review the topline results and provide a pipeline update. Interested parties may participate in the call via the following webcast link:

https://viaavid.webcasts.com/starthere.jsp?ei=1765661&tp_key=0d6c454cfe

Or use the following dial-in options:

US-based Investors: 1-877-407-4018

International Investors: 1-201-689-8471

Conference ID: 13760937

A replay of the webcast and accompanying slides will be available for 90 days following the event through the "Events and Presentations" page of the "Investors and Media" section of the company's website.

- ENDS -

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis' highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neurological diseases. Licaminlimab is a novel, topical anti-TNF α in a registrational trial, and is being developed with a genotype-based approach for treating patients with dry eye disease (DED). Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis Contact

Ms. Sylvia Cheung, CFO

sylvia.cheung@oculis.com

**Investor Relations**

LifeSci Advisors

Corey Davis, Ph.D.

cdavis@lifesciadvisors.com**Media Relations**

ICR Healthcare

Amber Fennell

oculis@icrhealthcare.com**Cautionary Statement Regarding Forward Looking Statements**

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company's product candidates, the initiation, timing, progress and results of current and future clinical trials, Oculis' research and development programs, regulatory and business strategy; Oculis' future development plans; the timing or likelihood of regulatory filings and approvals; and Oculis' cash runway are forward-looking. The clinical trial results presented in this press release are topline and preliminary and subject to change, as analysis is ongoing. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis' control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis' annual report on Form 20-F and any other documents filed with the SEC. Copies of these documents are available on the SEC's website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.



OCS-01

Phase 3 DIAMOND Trials

Topline Results in DME

May 29, 2026



Safe Harbor Statements

Cautionary note on forward-looking statements

These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements. For example, all statements we make regarding our regulatory and development plans for OCS-01 in diabetic macular edema or other indications, the timing, progress and regulatory strategy for our other research and development programs, our cash runway and statements about the potential therapeutic effects of our product candidates are forward-looking. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. The clinical trial results presented in this presentation are topline and preliminary and subject to change, as analysis is ongoing. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the possibility that Oculis may be adversely affected by economic, business, and/or competitive factors; Oculis' estimates of expenses and profitability; Oculis' ability to develop, manufacture and commercialize the product candidates in its pipeline; actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; the ability of Oculis or its partners to enroll and retain patients in clinical studies; the ability of Oculis or its partners to gain approval from regulators for planned clinical studies, study plans or sites; Oculis' ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; the success of Oculis' current and future collaborations, joint ventures, partnerships or licensing arrangements; financial position, strategy and anticipated milestones; and other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Oculis may from time to time file or furnish with the SEC. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Phase 3 DIAMOND Program Topline Results Summary

	DIAMOND-1	DIAMOND-2
Visual function: Primary endpoint not met Mean Change in BCVA from Baseline at Week 52	<ul style="list-style-type: none"> • OCS-01: 1.2 letters • Vehicle: 5.1 letters 	<ul style="list-style-type: none"> • OCS-01: 4.6 letters • Vehicle: 5.2 letters
Retinal anatomy: Rapid and sustained reduction Mean Change in CST from Baseline at Week 52	<ul style="list-style-type: none"> • OCS-01: -51.8 μm • Vehicle: -31.7 μm 	<ul style="list-style-type: none"> • OCS-01: -64.3 μm • Vehicle: -18.8 μm
Safety	OCS-01 was well tolerated with no unexpected safety findings	

At this time, Oculis does not plan to pursue FDA regulatory filing with OCS-01 for DME

Study Design and Patient Population

OCS-01 | Phase 3 DIAMOND Program in DME

Objective

Evaluate the safety and efficacy of OCS-01 vs vehicle for the treatment of DME in two adequate and well-controlled global Phase 3 clinical trials

Endpoints

Primary endpoint:


- Change in BCVA ETDRS letter score at Week 52

Key secondary endpoint:

- % with a ≥ 15 ETDRS letter gain in BCVA at Week 52
- CST change vs Baseline

Study Population

- Age 18-85 years
- Confirmed diagnosis of DME
- Diabetes mellitus 1 and 2
- ETDRS BCVA letter score: 65-24
- Retinal thickness (CST) ≥ 310 μm




BCVA: best corrected visual acuity; CST: central subfield thickness; DME: diabetic macular edema; ETDRS: Early Treatment Diabetic Retinopathy Study
VEGF: vascular endothelial growth factor.
Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Diabetic Macular Edema. ClinicalTrials.gov identifier: NCT05066997
Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema (DIAMOND-2). ClinicalTrials.gov identifier: NCT06172257


Diamond Patient Disposition

ITT Population

DIAMOND-1



DIAMOND-2



Diamond Baseline Demographics

ITT Population

Parameter	DIAMOND-1		DIAMOND-2	
	OCS-01 (N=200)	Vehicle (N=203)	OCS-01 (N=200)	Vehicle (N=201)
Age, mean years (SD)	63.5 (9.77)	64.2 (9.57)	65.0 (8.68)	64.7 (8.33)
Sex, n (%)				
Male	120 (60.0)	111 (54.7)	113 (56.5)	108 (53.7)
Female	80 (40.0)	92 (45.3)	87 (43.5)	93 (46.3)
Duration of DME, mean months (SD)	21.95 (33.866)	25.20 (34.352)	23.62 (32.916)	24.16 (40.082)
BCVA, mean ETDRS letter score (SD)	58.2 (7.37)	57.8 (8.02)	57.2 (9.21)	57.2 (7.62)
CST, mean μm (SD)	458.8 (117.35)	453.4 (128.22)	457.9 (145.77)	466.0 (147.83)
IOP, mean mm Hg (SD)	14.8 (2.95)	14.9 (3.08)	14.6 (2.95)	14.6 (2.78)
Treatment status, n (%)				
Naïve	109 (54.5)	102 (50.2)	101 (50.5)	97 (48.3)
Previously-treated	91 (45.5)	101 (49.8)	99 (49.5)	104 (51.7)
Lens status, n (%) *				
Phakic	125 (62.5)	128 (63.1)	119 (59.5)	118 (58.7)
Pseudo phakic	75 (37.5)	75 (36.9)	80 (40.0)	83 (41.3)


BCVA: best corrected visual acuity; CST: central subfield thickness; DME: diabetic macular edema; ETDRS: Early Treatment Diabetic Retinopathy Study;
 ITT: intention-to-treat; SD: standard deviation.
 *1 patient in DIAMOND-2 OCS-01 arm was aphakic

Diamond | **Oculis**

Efficacy


Mean Change in CST, Baseline to Week 52

ITT Population




Mean Change in CST, Baseline to Week 52

ITT Population




Visual Function: Primary Endpoint Mean Change in BCVA from Baseline at Week 52

ITT Population



Visual Function: Key Secondary Endpoint ≥ 15 -Letter Gain in BVCA at Week 52

ITT Population



Safety

Safety Summary

- OCS-01 was well tolerated, with no unexpected adverse events observed.
- Overall safety profile was consistent with that of previous trials.
- As expected, elevated IOP and cataracts were higher in the OCS-01 treated patients in line with chronic use of steroid in DME.

Summary

OCS-01 DIAMOND TLR Summary and Pipeline Prioritization

- Despite showing a rapid, substantial and sustained reduction in retinal thickness in patients treated with OCS-01, primary (mean change in BCVA) and key secondary (≥ 15 -letter gainers) endpoints for both trials were not met at Week 52.
- Based on the results, at this time Oculis does not plan to pursue an FDA regulatory filing for OCS-01 in DME.
- Oculis will strategically focus resources on advancing our late-stage portfolio, including the Privosegtor platform, starting with the PIONEER program for Privosegtor in optic neuropathies, and the PREDICT-1 trial for Licaminlimab to drive precision medicine in dry eye disease.
- Financial position remains strong with \$278 million in cash, cash equivalents, and short-term investments as of March 31, 2026, providing cash runway into 2H 2029.

Oculis

Q&A

